Skip to main content
Erschienen in:

04.02.2020 | Research Paper

Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition

verfasst von: Jipei Liao, Zejia Yang, Brandon Carter-Cooper, Elizabeth T. Chang, Eun Yong Choi, Bhaskar Kallakury, Xuefeng Liu, Rena G. Lapidus, Kevin J. Cullen, Hancai Dan

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

We explored the role of the transcription factor, NF-κB, and its upstream kinase IKKβ in regulation of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma (HNSCC). We showed that cisplatin-resistant HNSCC cells have a stronger ability to migrate and invade, as well as display higher IKKβ/NF-κB activity compared to their parental partners. Importantly, we found that knockdown of IKKβ, but not NF-κB, dramatically impaired cell migration and invasion in these cells. Consistent with this, the IKKβ inhibitor, CmpdA, also inhibited cell migration and invasion. Previous studies have already shown that N-Cadherin, an epithelial-mesenchymal transition (EMT) marker, and IL-6, a pro-inflammatory cytokine, play important roles in regulation of HNSCC migration, invasion, and metastasis. We found that cisplatin-resistant HNSCC expressed higher levels of N-Cadherin and IL-6, which were significantly inhibited by CmpdA. More importantly, we showed that CmpdA treatment dramatically abated cisplatin-resistant HNSCC cell metastasis to lungs in a mouse model. Our data demonstrated the crucial role of IKKβ in control of migration, invasion, and metastasis, and implicated that targeting IKKβ may be a potential therapy for cisplatin-resistant metastatic HNSCC.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34 Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7–34
2.
Zurück zum Zitat Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424 Bray F et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424
4.
Zurück zum Zitat Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9–22CrossRef Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9–22CrossRef
5.
Zurück zum Zitat Braakhuis BJ, Brakenhoff RH, Leemans CR (2012) Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Ann Oncol 23(Suppl 10):x173–x177CrossRef Braakhuis BJ, Brakenhoff RH, Leemans CR (2012) Treatment choice for locally advanced head and neck cancers on the basis of risk factors: biological risk factors. Ann Oncol 23(Suppl 10):x173–x177CrossRef
6.
Zurück zum Zitat Thomas SM, Grandis JR (2009) The current state of head and neck cancer gene therapy. Hum Gene Ther 20(12):1565–1575CrossRef Thomas SM, Grandis JR (2009) The current state of head and neck cancer gene therapy. Hum Gene Ther 20(12):1565–1575CrossRef
7.
Zurück zum Zitat Specenier PM, Vermorken JB (2009) Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol 45(4–5):409–415CrossRef Specenier PM, Vermorken JB (2009) Current concepts for the management of head and neck cancer: chemotherapy. Oral Oncol 45(4–5):409–415CrossRef
8.
Zurück zum Zitat Smith A, Teknos TN, Pan Q (2013) Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol 49(4):287–292CrossRef Smith A, Teknos TN, Pan Q (2013) Epithelial to mesenchymal transition in head and neck squamous cell carcinoma. Oral Oncol 49(4):287–292CrossRef
9.
Zurück zum Zitat Molinolo AA et al (2009) Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45(4–5):324–334CrossRef Molinolo AA et al (2009) Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 45(4–5):324–334CrossRef
10.
Zurück zum Zitat Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24(17):2666–2672CrossRef Kalyankrishna S, Grandis JR (2006) Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 24(17):2666–2672CrossRef
12.
Zurück zum Zitat Rabinowits G, Haddad RI (2012) Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 48(11):1085–1089CrossRef Rabinowits G, Haddad RI (2012) Overcoming resistance to EGFR inhibitor in head and neck cancer: a review of the literature. Oral Oncol 48(11):1085–1089CrossRef
13.
Zurück zum Zitat Shostak K, Chariot A (2015) EGFR and NF-kappaB: partners in cancer. Trends Mol Med 21(6):385–393CrossRef Shostak K, Chariot A (2015) EGFR and NF-kappaB: partners in cancer. Trends Mol Med 21(6):385–393CrossRef
14.
Zurück zum Zitat Brown M et al (2008) NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets 12(9):1109–1122CrossRef Brown M et al (2008) NF-kappaB in carcinoma therapy and prevention. Expert Opin Ther Targets 12(9):1109–1122CrossRef
15.
Zurück zum Zitat Wang F et al (2009) Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 9(4):389–395CrossRef Wang F et al (2009) Current and potential inflammation targeted therapies in head and neck cancer. Curr Opin Pharmacol 9(4):389–395CrossRef
16.
Zurück zum Zitat Nottingham LK et al (2014) Aberrant IKKalpha and IKKbeta cooperatively activate NF-kappaB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene 33(9):1135–1147CrossRef Nottingham LK et al (2014) Aberrant IKKalpha and IKKbeta cooperatively activate NF-kappaB and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer. Oncogene 33(9):1135–1147CrossRef
17.
Zurück zum Zitat Ziegelbauer K et al (2005) A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 145(2):178–192CrossRef Ziegelbauer K et al (2005) A selective novel low-molecular-weight inhibitor of IkappaB kinase-beta (IKK-beta) prevents pulmonary inflammation and shows broad anti-inflammatory activity. Br J Pharmacol 145(2):178–192CrossRef
18.
Zurück zum Zitat Zhang Y et al (2016) Targeting IkappaB Kinase beta/NF-kappaB signaling in human prostate cancer by a novel IkappaB kinase beta inhibitor CmpdA. Mol Cancer Ther 15(7):1504–1514CrossRef Zhang Y et al (2016) Targeting IkappaB Kinase beta/NF-kappaB signaling in human prostate cancer by a novel IkappaB kinase beta inhibitor CmpdA. Mol Cancer Ther 15(7):1504–1514CrossRef
19.
Zurück zum Zitat Sun L et al (2012) MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 31(4):432–445CrossRef Sun L et al (2012) MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 31(4):432–445CrossRef
20.
Zurück zum Zitat Li Z et al (2016) A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation. Oncotarget 7(22):31892–31906PubMedPubMedCentral Li Z et al (2016) A positive feedback loop involving EGFR/Akt/mTORC1 and IKK/NF-kB regulates head and neck squamous cell carcinoma proliferation. Oncotarget 7(22):31892–31906PubMedPubMedCentral
21.
Zurück zum Zitat Brenner JC et al (2010) Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 32(4):417–426PubMedPubMedCentral Brenner JC et al (2010) Genotyping of 73 UM-SCC head and neck squamous cell carcinoma cell lines. Head Neck 32(4):417–426PubMedPubMedCentral
22.
Zurück zum Zitat Johnson DE, O’Keefe RA, Grandis JR (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15:234CrossRef Johnson DE, O’Keefe RA, Grandis JR (2018) Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol 15:234CrossRef
23.
Zurück zum Zitat Smith CW et al (1998) The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC. Clin Exp Metastasis 16(7):655–664CrossRef Smith CW et al (1998) The host environment promotes the development of primary and metastatic squamous cell carcinomas that constitutively express proinflammatory cytokines IL-1alpha, IL-6, GM-CSF, and KC. Clin Exp Metastasis 16(7):655–664CrossRef
24.
Zurück zum Zitat Choudhary MM et al (2016) Interleukin-6 role in head and neck squamous cell carcinoma progression. World J Otorhinolaryngol Head Neck Surg 2(2):90–97CrossRef Choudhary MM et al (2016) Interleukin-6 role in head and neck squamous cell carcinoma progression. World J Otorhinolaryngol Head Neck Surg 2(2):90–97CrossRef
25.
Zurück zum Zitat Sun W et al (2014) Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP-2 and MMP-9. Int J Oncol 44(5):1551–1560CrossRef Sun W et al (2014) Interleukin-6 promotes the migration and invasion of nasopharyngeal carcinoma cell lines and upregulates the expression of MMP-2 and MMP-9. Int J Oncol 44(5):1551–1560CrossRef
26.
Zurück zum Zitat Chen MF et al (2013) IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 12:26CrossRef Chen MF et al (2013) IL-6 expression predicts treatment response and outcome in squamous cell carcinoma of the esophagus. Mol Cancer 12:26CrossRef
27.
Zurück zum Zitat Kanazawa T et al (2007) Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol 264(7):815–821CrossRef Kanazawa T et al (2007) Interleukin-6 directly influences proliferation and invasion potential of head and neck cancer cells. Eur Arch Otorhinolaryngol 264(7):815–821CrossRef
28.
Zurück zum Zitat Li Z et al (2015) IKK phosphorylation of NF-kappaB at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancer. Am J Cancer Res 5(10):3098–3110PubMedPubMedCentral Li Z et al (2015) IKK phosphorylation of NF-kappaB at serine 536 contributes to acquired cisplatin resistance in head and neck squamous cell cancer. Am J Cancer Res 5(10):3098–3110PubMedPubMedCentral
29.
Zurück zum Zitat Vander Broek R et al (2014) Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB signaling. Oral Oncol 50(10):930–941CrossRef Vander Broek R et al (2014) Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-kappaB signaling. Oral Oncol 50(10):930–941CrossRef
30.
Zurück zum Zitat Van Waes C (2011) Targeting NF-kappaB in mouse models of lung adenocarcinoma. Cancer Discov 1(3):200–202CrossRef Van Waes C (2011) Targeting NF-kappaB in mouse models of lung adenocarcinoma. Cancer Discov 1(3):200–202CrossRef
31.
Zurück zum Zitat Wu Y et al (2009) Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15(5):416–428CrossRef Wu Y et al (2009) Stabilization of snail by NF-kappaB is required for inflammation-induced cell migration and invasion. Cancer Cell 15(5):416–428CrossRef
32.
Zurück zum Zitat Li CW et al (2012) Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res 72(5):1290–1300CrossRef Li CW et al (2012) Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res 72(5):1290–1300CrossRef
33.
Zurück zum Zitat Peinado H, Portillo F, Cano A (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48(5–6):365–375CrossRef Peinado H, Portillo F, Cano A (2004) Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48(5–6):365–375CrossRef
Metadaten
Titel
Suppression of migration, invasion, and metastasis of cisplatin-resistant head and neck squamous cell carcinoma through IKKβ inhibition
verfasst von
Jipei Liao
Zejia Yang
Brandon Carter-Cooper
Elizabeth T. Chang
Eun Yong Choi
Bhaskar Kallakury
Xuefeng Liu
Rena G. Lapidus
Kevin J. Cullen
Hancai Dan
Publikationsdatum
04.02.2020
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 2/2020
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-020-10021-7

Neu im Fachgebiet Onkologie

Neue chemotherapiefreie Kombinationstherapie punktet bei CLL

Zwischenergebnisse der Phase-III-Studie AMPLIFY sprechen dafür, dass die zeitlich begrenzte Behandlung mit Acalabrutinib und Venetoclax fitte Personen mit chronischer lymphatischer Leukämie länger leben lässt als eine Chemoimmuntherapie.

NRG1-Fusionen als neues, klinisch relevantes Target

Ergebnisse einer Phase-II-Studie deuten darauf hin, dass ein gegen HER3 und HER2 gerichteter Antikörper bei verschiedenen NRG1-Fusions-positiven Tumoren wirksam sein könnte. In den USA ist die Substanz bereits beschleunigt zugelassen worden.

Die aktuelle S3-Leitlinie zu CLL strotzt vor Neuerungen

Vor kurzem wurde eine neue, grundlegend überarbeite Version der S3-Leitlinie Chronische Lymphatische Leukämie (CLL) veröffentlicht.  Zu den wichtigsten Änderungen gehört, dass die Chemoimmuntherapie auf dem Rückzug ist.

Gluteuslappen nach Rektumkarzinom-Op. schützt vor Abszessen

Die Wunddeckung mit einem autologen Rotationslappen nach Entfernung eines Rektumkarzinoms konnte in einer randomisierten Studie gegenüber dem primären Wundverschluss vor allem in einer Hinsicht punkten: Sie führte deutlich seltener zu präsakralen Abszessen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.